Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News Briefs: Injunction Lifted On Medtronic’s CoreValve; Tentative J&J Hip Settlement

This article was originally published in The Gray Sheet

Executive Summary

A German court gives Medtronic the right to sell its CoreValve in Germany again. Johnson & Johnson has agreed to a tentative settlement of $4 billion to patients who received its ASR metal-on-metal hip. More news briefs.

You may also be interested in...



Abbott Enters Electrophysiology Fray With Topera, ACT Deals

The diversified company is entering the atrial fibrillation catheter ablation for the first time. It is acquiring Afib ablation mapping system maker Topera and has gained rights to buy catheter developer Advanced Cardiac Therapeutics.

Edwards Wins Latest Round In TAVI Patent Dispute With Medtronic

A jury in Delaware awarded Edwards $393.6 million in damages plus royalties after determining Medtronic’s CoreValve infringes Edwards’ Cribier patent. While Medtronic might be paying royalties to Edwards for the next several years, Medtronic also got some very positive news last week: FDA approved CoreValve for patients too sick for surgery months earlier than expected.

News Briefs: DePuy ASR Settlement; Tandem Diabetes IPO; AtriCure Trial

DePuy settles bulk of U.S. ASR suits. Tandem Diabetes closes $138 million IPO. AtriCure gets go-ahead for new AtriClip stroke. More news.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel